Psybio Therapeutics Corp
XTSX:PSYB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Psybio Therapeutics Corp
XTSX:PSYB
|
CA |
|
LSB Industries Inc
NYSE:LXU
|
US |
|
Burger Fuel Group Ltd
NZX:BFG
|
NZ |
|
OCI NV
AEX:OCI
|
NL |
|
Peraso Inc
NASDAQ:PRSO
|
US |
|
Inspecs Group PLC
LSE:SPEC
|
UK |
|
Philly Shipyard ASA
OSE:PHLY
|
NO |
|
Chison Medical Technologies Co Ltd
SSE:688358
|
CN |
|
Ausnutria Dairy Corp Ltd
HKEX:1717
|
CN |
Psybio Therapeutics Corp
PsyBio Therapeutics Corp. engages in the development of drugs intended for the treatment of mental health challenges and other disorders. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2011-02-08. The firm is developing a new class of drugs intended for the treatment of mental health challenges and other disorders. The firm is in the process of developing its portfolio of product candidates for sale in the pharmaceutical industry. The company has developed a technology platform that enables the generation of its formulation for its lead compound psilocybin, biosynthetic psilocybin, and other targeted tryptamines through a biosynthetic process using genetically modified bacteria through collaboration with Miami University-based in Oxford, Ohio. The firm utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon, which to develop precursors and analogs, both naturally and non-naturally occurring.
PsyBio Therapeutics Corp. engages in the development of drugs intended for the treatment of mental health challenges and other disorders. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2011-02-08. The firm is developing a new class of drugs intended for the treatment of mental health challenges and other disorders. The firm is in the process of developing its portfolio of product candidates for sale in the pharmaceutical industry. The company has developed a technology platform that enables the generation of its formulation for its lead compound psilocybin, biosynthetic psilocybin, and other targeted tryptamines through a biosynthetic process using genetically modified bacteria through collaboration with Miami University-based in Oxford, Ohio. The firm utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon, which to develop precursors and analogs, both naturally and non-naturally occurring.
